22 results
F-1/A
EVAX
Evaxion Biotech A/S
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
care and reducing the health care burden. The goal is to be able to predict which patients will respond to a given therapy. With Proof of Principle … .
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, includes
F-1
EVAX
Evaxion Biotech A/S
12 Jan 24
Registration statement (foreign)
5:17pm
sooner than expected.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA … , a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive
424B4
bj6v75cxxoeb
5 Nov 21
Prospectus supplement with pricing info
4:47pm
F-1/A
hk7fodif54
3 Nov 21
Registration statement (foreign) (amended)
7:50am
F-1
thp3pmnryd1u
26 Oct 21
Registration statement (foreign)
7:02am
6-K
EX-99.2
6a383 2a82mtoxlol7
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am
DRS
046cs hertl
25 Jun 21
Draft registration statement
12:00am
20-F
t6atyyh y1d4ussv9b
7 Apr 21
Annual report (foreign)
4:31pm
424B4
n0kx 8wgb
5 Feb 21
Prospectus supplement with pricing info
4:53pm
F-1/A
u2p l5pc8kigj2
1 Feb 21
Registration statement (foreign) (amended)
4:56pm
F-1/A
6lezcg
25 Jan 21
Registration statement (foreign) (amended)
7:01am
F-1/A
qj8znz
19 Jan 21
Registration statement (foreign) (amended)
5:05pm
F-1
EX-10.1
lzyx0r8pzlumf
8 Jan 21
Registration statement (foreign)
4:54pm
F-1
yby5vdmlmkv
8 Jan 21
Registration statement (foreign)
4:54pm
DRS/A
qz8pidayc8fbf6ubl1q
4 Jan 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.1
s4i5zw7l5 oyj
4 Jan 21
Draft registration statement (amended)
12:00am
DRS/A
8om8sv phkgk8wm
16 Dec 20
Draft registration statement (amended)
12:00am